Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;96(2):e13160.
doi: 10.1111/sji.13160. Epub 2022 Mar 20.

Role of the antigen presentation process in the immunization mechanism of the genetic vaccines against COVID-19 and the need for biodistribution evaluations

P Polykretis  1
Affiliations

Role of the antigen presentation process in the immunization mechanism of the genetic vaccines against COVID-19 and the need for biodistribution evaluations

P Polykretis. Scand J Immunol. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

FIGURE 1
FIGURE 1
Schematic representation of: (A) A human cell intaking the lipid nanoparticle (LNP) containing the mRNA, translating the SARS‐CoV‐2 spike protein and presenting it to the B‐cell receptor (BCR) of a B cell; (B) a human cell intaking the LNP containing the mRNA, translating the spike protein and presenting it to the T‐cell receptor (TCR) of a CD8+ lymphocyte via the MHC I antigen presentation process; (C) MHC I presenting peptides deriving from the proteasomal degradation of endogenous proteins to the T‐cell receptor (TCR) of a CD8+ lymphocyte; (D) MHC II presenting peptides deriving from the proteasomal degradation of exogenous proteins to T‐cell receptor (TCR) of a CD4+ lymphocyte
See this image and copyright information in PMC

References

    1. Sell S. How vaccines work: immune effector mechanisms and designer vaccines. Expert Rev Vaccines. 2019;18:993‐1015. - PubMed
    1. Mascellino MT, Di Timoteo F, De Angelis M, et al. Overview of the main anti‐SARS‐CoV‐2 vaccines: mechanism of action, Efficacy and Safety. Infect Drug Resist. 2021;14:3459‐3476. - PMC - PubMed
    1. Rock KL, Reits E, Neefjes J. Present yourself! By MHC Class I and MHC Class II molecules. Trends Immunol. 2016;37:724‐737. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383(27):2603‐2615. - PMC - PubMed
    1. SARS‐CoV‐2 mRNA Vaccine (BNT162, PF‐0 7302048): 2.6.5.5B. Pharmacokinetics: organ distribution continued, report number: 185350. Page 6. Accessed 23 July 2021. Available at: https://www.pmda.go.jp/drugs/2021/P20210212001/672212000_30300AMX00231_I...